Journals / MN Oftalmoloji / 2016 / Cilt: 23 - Sayı: 1

Glaucoma, Anti-Glaucomatous Medication and Dry Eye

Glokom, Glokom İlaçları ve Kuru Göz

Pages
91–95
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With this article, we aim to inform the reader about the epidemiology, causes, precautions and treatment ofocular surface disease in patients with glaucoma

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ocular surface disease is more likely to occur in patients with glaucoma treated with medical therapy.
📊
Key Findings & Data:The treatment of glaucoma and ocular surface disease is very difficult when occurred at the same time in a patient.
💡
Conclusion & Impact:With this article, we aim to inform the reader about the epidemiology, causes, precautions and treatment ofocular surface disease in patients with glaucoma
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ocular surface disease is more likely to occur in patients with glaucoma treated with medical therapy. The treatment of glaucoma and ocular surface disease is very difficult when occurred at the same time in a patient. In particular, the side effectsof anti-glaucomatous drugs containing preservatives, are at the forefront of the emergence of ocular surface disease in glaucoma patients. With this article, we aim to inform the reader about the epidemiology, causes, precautions and treatment ofocular surface disease in patients with glaucoma

Özet

Medikal tedavi alan glokom hastalarında, oküler yüzey hastalığı ortaya çıkma olasılığı fazladır. Hastada aynı anda karşımıza çıktıklarında, glokom ve oküler yüzey hastalıklarının tedavileri oldukça güçleşir. Özellikle koruyucu içeren antiglokomatöz ilaçların yan etkileri, glokom hastalarında oküler yüzey hastalığının ortaya çıkmasında ön plandadırlar. Bu yazı ile glokom hastalarında oküler yüzey hastalığının görülme sıklığı, sebepleri, önlemleri ve tedavisi hakkında okuyucuya bilgi vermeyi amaçlamaktayız

🔖

Cite This Article

BAYER, A., ÖZGE, G. (2016). Glaucoma, Anti-Glaucomatous Medication and Dry Eye. MN Oftalmoloji, Cilt: 23 - Sayı: 1, 91–95. https://ajindex.com/articles/295549

References (14)

  1. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Opht - hal mology 1998;105:1114-19
  2. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997; 124:723-28
  3. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
  4. Fechtner RD, Godfrey DG, Budenz D, et al. Pre va - lence of ocular surface complaints in patients with glaucoma using topical intraocular pressure lowering medications. Cornea 2010;29:618-21
  5. Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome related quality of life in glaucoma patients. Eur J Ophthalmol 2009;19:572-9
  6. Ghosh S, O’Hare F, Lamoureux E, et al. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Experiment Ophthalmol 2012;40:675-81
  7. Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990;108:1543-8
  8. Broadway DC, Grierson I, O’Brien C, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994; 112:1446-54
  9. Kozobolis VP, Christodoulakis EV, Naoumidi II, Siganos CS, Detorakis ET, Pallikaris LG. Study of conjunctival goblet cell morphology and tear film stability in pseudoexfoliation syndrome. Graefes Arch Clin Exp Ophthalmol 2004;242:478-83
  10. Akdemir MO, Kirgiz A, Ayar O, et al. The Effect of Pseudoexfoliation and Pseudoexfoliation Induced Dry Eye on Central Corneal Thickness. Curr Eye Res 2016;41:305-10
  11. Blondin C, Hamard P, Cholley B, et al. In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Curr Eye Res 2003;27:253-9 12. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45:1360-8
  12. Sosne G, Albeiruti AR, Hollis B, et al. Thymosin beta4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitro. Exp Eye Res 2006;83:502-7
  13. Clouzeau C, Godefroy D, Riancho L, et al. Hyperos - mo larity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro. Mol Vis 2012;18:851-63
  14. Pellinen P, Huhtala A, Tolonen A, et al. The cytotoxic effects of pre